📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007. (2018)

First Author: Synnott NC

Attributed to: Structural biology of the tumour suppressor p53 and its complexes funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.canlet.2017.09.053

PubMed Identifier: 29069577

Publication URI: http://europepmc.org/abstract/MED/29069577

Type: Journal Article/Review

Volume: 414

Parent Publication: Cancer letters

ISSN: 0304-3835